NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) announced that it filed its completed premarket approval application (PMA) for the LightTouch™ Cervical Scanner with the U.S. Food and Drug Administration (FDA) for patients at risk for cervical cancer. In a multi-center FDA-approved pivotal trial, the device found cervical disease up to two years earlier than with current standard-of-care screening and diagnostic techniques.
